AtriCure Inc. (NASDAQ:ATRC)’s share price rose 3.2% during trading on Wednesday . The stock traded as high as $15.02 and last traded at $14.95, with a volume of 121,024 shares changing hands. The stock had previously closed at $14.48.

A number of equities research analysts have recently weighed in on ATRC shares. Northland Securities started coverage on shares of AtriCure in a research note on Tuesday, March 29th. They issued an “outperform” rating and a $24.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of AtriCure in a research note on Monday, March 14th. Zacks Investment Research downgraded shares of AtriCure from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. TheStreet downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Monday, May 2nd. Finally, JMP Securities began coverage on shares of AtriCure in a research note on Thursday, June 30th. They issued an “outperform” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $24.67.

The stock’s market cap is $494.76 million. The stock has a 50-day moving average price of $14.79 and a 200 day moving average price of $16.72.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, April 28th. The medical device company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.01. The company had revenue of $35.90 million for the quarter, compared to the consensus estimate of $36.08 million. The company’s quarterly revenue was up 19.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.19) earnings per share. Analysts forecast that AtriCure Inc. will post ($1.19) earnings per share for the current fiscal year.

Several hedge funds and institutional investors recently bought and sold shares of ATRC. Tamarack Advisers LP bought a new position in AtriCure during the fourth quarter valued at $15,708,000. Paradigm Capital Management Inc. NY boosted its position in AtriCure by 108.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 247,525 shares of the medical device company’s stock valued at $5,554,000 after buying an additional 128,700 shares during the period. Wells Fargo & Company MN boosted its position in AtriCure by 20.2% in the fourth quarter. Wells Fargo & Company MN now owns 659,070 shares of the medical device company’s stock valued at $14,789,000 after buying an additional 110,890 shares during the period. Finally, Victory Capital Management Inc. boosted its position in AtriCure by 15.3% in the fourth quarter. Victory Capital Management Inc. now owns 51,647 shares of the medical device company’s stock valued at $1,159,000 after buying an additional 6,845 shares during the period.

AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System, which includes its Isolator Synergy clamps, generator and switchbox, is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting, and valve replacement or repair.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.